The common cold is the most pervasive recurring illness on earth. For years, people have turned to nonsteroidal anti-inflammatory drugs, or NSAIDs, to relieve pain, fever and other symptoms related to the miserable feelings brought on by the common cold. NSAIDs include ibuprofen, which is available in brands such as Motrin and Advil, and naproxen, which is marketed as Aleve.
A new Cochrane review of nine studies has found that NSAIDs are effective in reducing many cold symptoms. It is important to note, however, that NSAIDs can relieve symptoms of the common cold – not prevent or treat the illness.
“The review found that NSAIDs improved most analgesia-related symptoms such as headache, ear pain, and muscle and joint pain,” said lead author Soo Young Kim, MD, a professor at HallymUniversityMedicalCollege in Seoul, South Korea. “We also found that NSAIDs significantly improved sneezing associated with the common cold.”
Kim and his colleagues looked at whether NSAIDs were more effective than placebos for reducing common cold symptoms. The studies included 1,064 children and adults suffering from a cold. The participants did not have an acute illness or a chronic health condition. In six studies, 891 participants had acquired the cold before the study began, while 178 participants in three other studies were infected deliberately. Treatment duration ranged from a single dose to two doses a day for seven days.
The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews like this one draw evidence-based conclusions abut medical practice after considering both the content and quality of existing medical trials on a topic.
The investigators found that NSAIDs are beneficial in treating many cold symptoms, but not all cold symptoms. “That’s due to the fact that many symptoms of the common cold are caused by inflammation due to viruses that do not appear in a single pathway,” Kim said.
For example, reviewers found no clear evidence that NSAIDs are effective in improving respiratory symptoms such as cough and nasal discharge. “If a person has a cough caused by a cold, the AmericanCollege of Chest Physicians has recommended the administration of naproxen,” Kim said. “Further research is needed to evaluate the benefits of NSAIDs for relieving respiratory symptoms.”
Norman Edelman MD, chief medical officer of the American Lung Association, agrees with the review findings.
“Nonsteroidal anti-inflammatory drugs provide relief for many symptoms of the common cold,” he said. “Even though they alleviate cold symptoms for many patients, it is unlikely that consumers expect NSAIDs to provide relief from all symptoms of the common cold. The review confirms the behavior of many consumers who are looking for a reduction of cold symptoms.”
Edelman noted that while the review investigated common cold symptoms and not the flu, it did not distinguish the difference between cold and influenza symptoms.
“Even though fever is associated with the flu, not every person who is taking an NSAID recognizes that,” he said. “If they are taking an NSAID to treat common cold symptoms, they may think their fever is due to a cold, but in realty, it may be influenza.”
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.